PS Ratio
17.95
+0.26+1.47%
Fri, 07 Feb 2025 00:54:37 GMT
Summary
- As of February 7, 2025, LCTX price to sales ratio is 17.95, with a rise of +0.26 (+1.47%) during the most recent trading day.
- Over the past year, LCTX PS ratio has dropped by -5.44 (-23.26%).
- LCTX PS ratio is now -99.51% below its all-time high of 3672.60.
Performance
LCTX PS Ratio Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
PS Ratio Formula
P/S = Market capitalization
TTM Revenue
Market capitalization
TTM Revenue
TTM Revenue
LCTX PS Ratio Trends
| PeriodPeriod | PS ratioPS ratio | PricePrice | Market capMarket cap | TTM revenueTTM revenue |
|---|---|---|---|---|
| todaytoday | +1.5% | +1.4% | +1.4% | +41.0% |
| 1 m1 month | +24.7% | +24.7% | +24.7% | - |
| 3 m3 months | -10.9% | -23.7% | -10.9% | +41.0% |
| 6 m6 months | -36.1% | -22.8% | -9.9% | - |
| ytdytd | +36.8% | +36.8% | +36.8% | - |
| 1 y1 year | -23.3% | -36.0% | -25.2% | -0.6% |
| 5 y5 years | -86.5% | -45.8% | -20.3% | +868.8% |
LCTX PS Ratio Highs & Lows
| PeriodPeriod | HighHigh | Current vs highvs high | LowLow | Current vs lowvs low | |
|---|---|---|---|---|---|
| 1 m | 1-month | at high | 14.23 | +26.1% | |
| 3 m | 3-month | 21.01 | -14.6% | 12.64 | +42.0% |
| 6 m | 6-month | 29.49 | -39.1% | 12.64 | +42.0% |
| 1 y | 1-year | 35.14 | -48.9% | 12.64 | +42.0% |
| 3 y | 3-year | 68.30 | -73.7% | 12.60 | +42.5% |
| 5 y | 5-year | 613.97 | -97.1% | 12.60 | +42.5% |
| alltime | all time | 3672.60 | -99.5% | 4.10 | +337.8% |
Lineage Cell Therapeutics PS Ratio History
| Date | Value |
|---|---|
| 2025 | 17.95(+36.8%) |
| 2024 | 13.12(-38.5%) |
| 2023 | 21.32(+57.5%) |
| 2022 | 13.54(-87.3%) |
| 2021 | 106.58(-69.4%) |
| 2020 | 348.58(+286.4%) |
| 2019 | 90.21(+10.4%) |
| 2018 | 81.70(-46.3%) |
| 2017 | 152.21(-8.1%) |
| 2016 | 165.63(+13.1%) |
| 2015 | 146.42(-2.3%) |
| 2014 | 149.94(+110.1%) |
| 2013 | 71.37(-22.1%) |
| 2012 | 91.61(-46.9%) |
| 2011 | 172.55(-36.4%) |
| 2010 | 271.47(+267.0%) |
| 2009 | 73.98(+164.1%) |
| Date | Value |
|---|---|
| 2008 | 28.01(+210.2%) |
| 2007 | 9.03(+72.0%) |
| 2006 | 5.25(-31.6%) |
| 2005 | 7.67(-80.4%) |
| 2004 | 39.07(+15.4%) |
| 2003 | 33.87(-37.3%) |
| 2002 | 54.04(-84.7%) |
| 2001 | 352.11(-73.0%) |
| 2000 | 1306.39(+1302.3%) |
| 1999 | 93.16(-38.5%) |
| 1998 | 151.59(-51.4%) |
| 1997 | 311.76(+4.6%) |
| 1996 | 298.04(+936.7%) |
| 1995 | 28.75(+63.8%) |
| 1994 | 17.55(-60.9%) |
| 1993 | 44.91(-19.2%) |
| 1992 | 55.60 |
FAQ
- What is Lineage Cell Therapeutics price to sales ratio?
- What is the all time high PS ratio for Lineage Cell Therapeutics?
- What is LCTX price to sales ratio year-to-date change?
- What is Lineage Cell Therapeutics PS ratio year-on-year change?
What is Lineage Cell Therapeutics price to sales ratio?
The current PS ratio of LCTX is 17.95
What is the all time high PS ratio for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high price to sales ratio is 3672.60
What is LCTX price to sales ratio year-to-date change?
Lineage Cell Therapeutics price to sales ratio has changed by +4.83 (+36.81%) since the beginning of the year
What is Lineage Cell Therapeutics PS ratio year-on-year change?
Over the past year, LCTX price to sales ratio has changed by -5.44 (-23.26%)